Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Pierre-Fabre-OBGEMSA

More Like This

PR Newswire associated0

Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.

PR Newswire associated0

UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

PR Newswire associated0

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)

PR Newswire associated0

Vueway® (Gadopiclenol) Receives Positive CHMP Opinion

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

PR Newswire associated0

Stimvia Expands Scientific Advisory Board and Commercial Leadership to Advance Global Market Expansion of Flagship URIS® Therapy